摘要
目的 探讨放化疗联合特瑞普利单抗治疗Ⅲ期非小细胞肺癌(NSCLC)的疗效.方法 将87例Ⅲ期NSCLC患者按照治疗方式的不同分为常规放化疗组(43例)、联合特瑞普利组(44例).检测治疗前后两组患者鳞状细胞癌相关抗原(SCC-Ag)、胸苷激酶1(TK1)、癌胚抗原(CEA)、血管内皮生长因子(VEGF)、糖类抗原125(CA125)和T淋巴细胞亚群水平,记录不良反应发生情况.结果 治疗后,两组患者SCC-Ag、TK1、CEA、VEGF、CA125水平均较治疗前降低,CD3+、CD4+、CD8+水平均较治疗前升高,联合特瑞普利组患者SCC-Ag、TK1、CEA、VEGF、CA125、CD8+水平均低于常规放化疗组,CD3+、CD4+水平均高于常规放化疗组,差异均有统计学意义(P﹤0.05).联合特瑞普利组患者不良反应总发生率低于常规放化疗组,差异有统计学意义(P﹤0.05).结论 放化疗联合特瑞普利单抗治疗Ⅲ期NSCLC患者,可降低肿瘤标志物水平,提高机体免疫力,不良反应较少.
Abstract
Objective To investigate the efficacy of chemoradiotherapy combined with toripalimab in the treatment of stage Ⅲ non-small cell lung cancer(NSCLC).Method A total of 87 patients with stage Ⅲ NSCLC were divided into conventional chemoradiotherapy group(43 cases)and combined with toripalimab group(44 cases)according to different treatment methods.The levels of squamous cancinoma-associated antigen(SCC-Ag),thymidine kinase 1(TK1),carcino-embryonic antigen(CEA),vascular endothelial growth factor(VEGF),carbohydrate antigen 125(CA125)and T lympho-cyte subgroups were detected before and after treatment,and the occurrence of adverse reactions was recorded.Result After treatment,the levels of SCC-Ag,TK1,CEA,VEGF and CA125 were decreased,while the levels of CD3+,CD4+ and CD8+ were increased in the two groups,the levels of SCC-Ag,TK1,CEA,VEGF,CA125 and CD8+ in combined with toripalimab group were lower than those in conventional chemoradiotherapy group,while the levels of CD3+ and CD4+ were higher than those in conventional chemoradiotherapy group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in combined with toripalimab group was lower than that in conventional chemoradiotherapy group,and the difference was statistically significant(P<0.05).Conclusion Chemoradiotherapy combined with toripalimab in the treatment of stage III NSCLC patients can reduce the tumor markers level,improve im-munity,and have less adverse reactions.
维普
万方数据